We are pleased to share another set of customer-provided third-party laboratory testing results from ILS Laboratories, USA, conducted on August 11–12, 2026.
The submitted Certificates of Analysis (COAs) cover six research compounds, with the following reported HPLC purity results:
- BPC-157 / TB-500 (20mg) — 99.82%
- GLOW Blend (70mg) — 99.72%
- NAD+ (1000mg) — 98.67%
- Selank (10mg) — 99.18%
- Semax (10mg) — 99.00%
- TB-500 (10mg) — 98.15%
All six reports indicated successful identity confirmation and purity results meeting the laboratory reports’ specified acceptance criteria. Fentanyl screening was reported as “Not Detected” at the stated testing cutoff.
Customer-Shared Laboratory Reports
[Insert Image 1: BPC-157 / TB-500 — 99.82%]
[Insert Image 2: GLOW — 99.72%]
[Insert Image 3: NAD+ — 98.67%]
[Insert Image 4: Selank — 99.18%]
[Insert Image 5: Semax — 99.00%]
[Insert Image 6: TB-500 — 98.15%]
Transparency Through Independent Testing
We appreciate customers who voluntarily share their independent laboratory findings.
Third-party analytical reports provide valuable information about sample identity, purity, and measured content, supporting greater transparency and traceability in the research chemical industry.
Research Use Only: Results apply exclusively to the specific tested samples and batches. These findings do not establish clinical safety, efficacy, or suitability for human use. Products are intended for laboratory research only.
